The review considers the major nonglycemic effects of dipeptidyl peptidase-4 inhibitors commonly used in diabetological practice, by using as an example sitagliptin, the first and most investigated representative of this class.
A S Ametov, L L Kamynina. Nonglycemic effects of dipeptidyl peptidase-4 inhibitors]. TerapevticheskiÄ arkhiv. 2013;85(1):98-102
PMID: 23536954
View Full Text